Escherichia Coli Strain Market, By Strain Type (Commensal strains, Diarrheal strains, Extraintestinal pathogenic strains, Uropathogenic strains, Neonatal meningitis strains, and Others), By Application (Diagnostics, Research, Therapeutics, Production of recombinant proteins, Quality control organisms, and Others), By Pathogenicity (Pathogenic E. coli and Non-pathogenic E. coli), By End User (Research Institutes, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
The escherichia coli strain market is expected to reach US$ 3.14 Bn by 2030 from US$ 1.97 Bn in 2023; and is expected to exhibit a compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
The growth of the escherichia coli strain market is due to factors such as increasing E. coli testing, growing product innovations, and rising research activities. On the other hand, testing challenges is the major factor limit the market growth.
Escherichia Coli Strain Market Regional Insights
North America is expected to dominate the market with a market share of 33.1% in 2023. This is due to the increasing awareness of foodborne illnesses and the rising demand for efficient diagnostic methods in the region.
Europe is the second-largest market for escherichia coli strain, with a market share of 27.2% in 2023. This is due to the well-established healthcare infrastructure and the increasing government initiatives to improve food safety in the region.
Asia Pacific is expected to be the fastest-growing market for escherichia coli strain, with a CAGR of 7.4% from 2023 to 2030. This is due to the growing population, increasing urbanization, and the rising demand for food safety in the region.
Figure 1. Global Escherichia Coli Strain Market Share (%), By Region, 2023
Global escherichia coli (E. coli) strain market is poised for significant growth in the coming years. This growth is primarily driven by the increasing prevalence of E. coli infections and the rising demand for effective diagnostic and therapeutic solutions.E. Coli, a common type of bacteria that can cause various types of infections, including urinary tract infections, respiratory illness, and pneumonia, is becoming a major public health concern worldwide. The rising incidence of these infections is expected to drive the demand for E. coli strain products for diagnostic and research purposes. However, the market faces challenges such as stringent regulatory guidelines for the approval of new diagnostic tests and treatments, and the high cost of advanced E. coli strain products. From a geographical perspective, North America is expected to hold a significant share in the global E. coli strain market, owing to the advanced healthcare infrastructure and high investment in research and development activities in the region. Meanwhile, the Asia Pacific region is anticipated to witness the fastest growth due to increasing healthcare expenditure and growing awareness about E. coli infections. In conclusion, the global E. coli strain market is expected to witness significant growth, driven by increasing E. Coli infections, advancements in biotechnology and microbiology, and rising investment in research and development activities. However, market players need to address challenges such as stringent regulatory guidelines and high product costs to ensure sustained growth.
Escherichia Coli Strain Market Drivers
Biotechnology research: E. coli strains are commonly used as model organisms in biotechnology Their well-understood genetics and fast growth make them valuable tools for studying various biological processes. Advancements in biotechnology research leads to an increased demand for E. coli strains and their derivatives.
Recombinant protein production: E. coli is widely used for producing recombinant proteins, including therapeutic proteins and enzymes, through genetic engineering techniques. As the demand for these proteins in medicine, industry, and agriculture increases, so does the demand for specific E. coli strains optimized for protein expression.
Pharmaceutical development: E. coli strains are used in the early stages of pharmaceutical development, especially for the production of candidate drugs, diagnostic reagents, and vaccine antigens. The discovery and development of new pharmaceutical products drives the demand for specific E. coli strains tailored to these applications.
Industrial processes: E. coli strains can be employed in various industrial processes, such as biofuel production, bioremediation, and bioplastics As industries seek more sustainable and environmentally friendly solutions, the demand for E. coli strains with specific metabolic capabilities rises.
Escherichia Coli Strain Market Opportunities
Product approvals: The market players are focused on the approvals of products for the detection of E. coli presence in water and this is expected to drive the market growth over forecast period. For instance, in June 2021, Bio-Rad Laboratories, Inc., a global biotechnology company announced that it has received U.S. Environmental Protection Agency (EPA) approval for the its RAPID'E.coli 2 Agar Environmental Protection Agency (EPA) for testing drinking water for Escherichia coli (E. coli) and total coliforms.
Biopharmaceutical production: The demand for biopharmaceuticals, including therapeutic proteins and antibodies, continues to grow. E. coli strains are used in the production of these biologics. Market opportunities exist for companies that can develop and provide high-yield E. coli strains optimized for protein expression and post-translational modifications.
Synthetic biology: The field of synthetic biology offers vast potential for developing novel organisms and biosystems. Companies can explore market opportunities by engineering E. coli strains with new functionalities, such as biosynthesis of novel chemicals, biofuels, or high-value compounds for industrial applications.
Personalized medicine: Advances in genomics and precision medicine are driving the development of personalized therapies. E. coli strains can be utilized to produce personalized therapeutic proteins or vaccines that are tailored to individual patients. Companies can explore opportunities in this area to provide custom-made E. coli strains for precision medicine applications.
Escherichia Coli Strain Market Report Coverage
Report Coverage
Details
Base Year:
2022
Market Size in 2023:
US$ 1.97 Bn
Historical Data for:
2017 to 2021
Forecast Period:
2023 - 2030
Forecast Period 2023 to 2030 CAGR:
6.9%
2030 Value Projection:
US$ 3.14 Bn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
By Strain Type: Commensal strains, Diarrheal strains, Extraintestinal pathogenic strains, Uropathogenic strains, Neonatal meningitis strains, and Others
By Application: Diagnostics, Research, Therapeutics, Production of recombinant proteins, Quality control organisms, and Others
By Pathogenicity: Pathogenic E. coli and Non-pathogenic E. coli
By End User: Research Institutes, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others
Companies covered:
Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Sanofi, and Xiamen Innovax Biotech Co., Ltd
Advanced genetic engineering techniques: The development and application of advanced genetic engineering techniques, such as CRISPR-Cas9 and synthetic biology tools, have significantly impacted the E. coli strain market. These tools allow researchers to modify E. coli strains more precisely and efficiently, thereby leading to the creation of strains with improved characteristics for various applications.
Rising demand for biopharmaceuticals: The demand for biopharmaceuticals, including therapeutic proteins and antibodies produced using E. coli strains, has been steadily increasing. E. coli remains a popular host for biopharmaceutical production due to its ease of use, scalability, and cost-effectiveness. The market trend involves optimizing E. coli strains for higher protein yields and better post-translational modifications.
Environmental and sustainable solutions: The push for more environmentally friendly and sustainable solutions in various industries has led to increased interest in E. coli strains for bioremediation, biofuel production, and other sustainable applications. E. coli's versatility in metabolizing various feedstocks makes it attractive for these purposes.
Personalized medicine and precision biotechnology: With advancements in genomics and precision medicine, there is a growing trend towards personalized medicine. E. coli strains are being engineered to produce customized therapeutic proteins, vaccines, and other bioactive molecules tailored to individual patients' needs.
Escherichia Coli Strain Market Restraints
Safety and biosecurity concerns: E. coli strains, particularly certain pathogenic strains, can pose safety risks if mishandled or accidentally released into the environment. As the use of E. coli strains expands in various applications, ensuring proper containment and biosafety measures is essential to mitigate potential risks.
Regulatory hurdles: The use of E. coli strains, especially genetically modified variants, is subject to stringent regulatory oversight. Navigating through complex regulatory pathways and obtaining approvals for novel applications can be time-consuming and costly for companies working in this field.
Competition from other microorganisms: While E. coli is widely used in research and biotechnology, it faces competition from other microbial hosts, such as yeast, mammalian cells, and other bacterial strains, for specific applications. Selecting the most suitable host organism can be a challenge that is based on the specific requirements of each application.
Contamination and cross-contamination risks: In research laboratories and industrial settings, there is always a risk of contamination and cross-contamination, which can lead to inaccurate results or compromised production processes. Maintaining strict quality control measures is necessary to prevent these issues.
Counterbalance: E.coli strains should be handled very carefully, in order to prevent its accidental release and lessen potential risks. It is necessary to maintain safety measure to prevent contamination and cross-contamination risks.
Recent Developments
Agreements
On October 03, 2023, Sanofi, a global pharmaceutical company announced that it has entered into an agreement with Janssen Global Services, LLC, a global pharmaceutical company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli
Key Strategic Initiatives
In March 2021, Xiamen Innovax Biotech Co., Ltd, a China based biopharmaceutical company initiated a study Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) for the treatment of conditions such as Cervical Intraepithelial Neoplasia. The study is expected to be completed in January, 2024.
Figure 2. Global Escherichia Coli Strain Market Share (%), By Strain Type, 2023
Definition: The Escherichia Coli (E. coli) strain market refers to the global business sector involved in the research, development, production, and distribution of different strains of the E. Coli bacteria for various applications. E. Coli is a type of bacteria that normally lives in the intestines of people and animals. The escherichia coli strain market refers to the commercial and industrial market for various strains of escherichia coli bacteria, which are used in diverse fields such as biotechnology, pharmaceuticals, agriculture, and biofuel production for various applications such as gene expression, protein production, research, and development.
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
The global Escherichia Coli Strain Market size was valued at USD 1.97 billion in 2023 and is expected to reach USD 3.14 billion in 2030.
The major factors driving the escherichia coli strain market growth are biotechnology research, recombinant protein production, pharmaceutical development, and industrial processes.
Growing demand for biotechnological applications, such as gene expression and protein production, Increasing adoption of E. coli strains in pharmaceutical research and vaccine development & Expanding applications in the agriculture and biofuel industries.
The major players operating in the escherichia coli strain market are Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Sanofi , and Xiamen Innovax Biotech Co., Ltd.
North America leads the escherichia coli strain market.
The CAGR of the escherichia coli strain market is 6.9%.
Increasing applications in biotechnology and pharmaceutical research, Growing demand for sustainable and eco-friendly production processes & Expanding use in agriculture and biofuel industries.
U.S.: 
U.K. : 
India : 
